StockData
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

CHAMPIONS ONCOLOGY, INC.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)

Close on Oct 19, 2026

Market cap
$65.18M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Dec 14, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q1 FY2027
Ended Jul 31, 2026
Sep 10, 2026After market close$15.20M––
Q4 FY2026
Ended Apr 30, 2026
Jul 27, 2026After market close$13.80M$-0.05$0.01
Q3 FY2026
Ended Jan 31, 2026
Mar 12, 2026After market close$16.60M$-0.02$0.04
Q2 FY2026
Ended Oct 31, 2025
Dec 15, 2025After market close$15.00M$0.02$0.06
Q1 FY2026
Ended Jul 31, 2025
Sep 15, 2025After market close$14.00M$-0.03$0.02
Q4 FY2025
Ended Apr 30, 2025
Jul 23, 2025After market close$12.30M$-0.13$-0.07
Q3 FY2025
Ended Jan 31, 2025
Mar 11, 2025After market close$17.00M––
Q2 FY2025
Ended Oct 31, 2024
Dec 11, 2024After market close$13.50M$0.05$0.05
Q1 FY2025
Ended Jul 31, 2024
Sep 11, 2024After market close–––
Q4 FY2024
Ended Apr 30, 2024
Jul 18, 2024After market close–––
Q3 FY2024
Ended Jan 31, 2024
Mar 12, 2024After market close–––

Company guidance

Outlook given with results on Dec 11, 2024, compared with the previous outlook

MeasurePeriodGuidancevs. prior
revenue growththe year10% to 15% growthNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Champions Oncology filed with the SEC